MAPT and Cognitive impairment: Plasma p‐tau species, such as p‐tau217, have shown performance comparable to that of CSF in research cohorts in distinguishing between healthy controls, preclinical AD, other neurodegenerative disorders and AD with cognitive impairment.13, 14, 15